Qiagen’s Thierry Bernard named chair of the AdvaMedDx board

Name: Thierry Bernard

New title: Chair of the board of directors of AdvaMedDx

Concurrent title: CEO of Qiagen

Qiagen CEO Thierry Bernard has been elected chair of the AdvaMedDx board of directors, succeeding Bio-Rad Laboratories CEO Norman Schwartz.

AdvaMedDx is a division of the trade group AdvaMed, representing more than 75 manufacturers of in-vitro diagnostic tests and technologies in the U.S. and abroad.

Bernard joined Netherlands-based Qiagen in 2015 and was named CEO in 2019. He worked for 15 years at bioMérieux, where he most recently served as corporate vice president for global commercial operations.

“AdvaMedDx is well positioned and has the opportunity to ensure that patients and providers have access to reliable, precise diagnostics. I am excited to lead the AdvaMedDx Board of Directors, and I look forward to working with my colleagues to continue to make a meaningful impact on the diagnostics landscape and improve the lives of countless individuals around the world,” Bernard said in a statement.